BioPharma Dive December 10, 2024
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned class of heart medicines called CETP inhibitors.
An experimental drug from NewAmsterdam Pharma has shown it may protect heart health in a Phase 3 study, a finding Wall Street analysts believe boosts the medicine’s chances of improving the outcomes of people with cardiovascular disease in an ongoing, closely watched clinical trial.
NewAmsterdam on Tuesday said the drug, obicetrapib, met its main goal in the third of three late-stage trials. People with either an inherited condition called heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who received obicetrapib alongside other medicines saw their levels of LDL, or “bad,” cholesterol fall by an average of...
Today's Sponsors
Today's Sponsor